Benzene and Acute Myeloid Leukemia: Examining the Causal Link

From General Health to Occupational Risk

In the domain of mass production, the legacy of general health and science information has long emphasized broad public health principles, such as hygiene, nutrition, and disease prevention, often communicated through accessible channels. This foundational context historically addressed environmental risks in a generalized manner, focusing on community-level exposures and lifestyle factors. As industrial processes expanded, the need arose to translate these general health frameworks into more specific occupational settings, where workers face distinct and concentrated hazards. The bridge concept here involves shifting from a population-wide perspective to a targeted examination of workplace environments, particularly those involving chemical agents. Within this transition, benzene exposure emerges as a critical concern due to its prevalence in manufacturing processes, such as in the production of plastics, resins, and synthetic fibers. The focus narrows from abstract health promotion to the concrete risks of chronic inhalation or dermal contact in industrial settings. This pivot acknowledges that while general health information provides a baseline for understanding toxicity, occupational contexts demand a more precise evaluation of exposure levels, duration, and control measures. Thus, the transition moves from broad educational content to a pragmatic assessment of how benzene, as a common industrial solvent, may elevate the risk of acute myeloid leukemia among workers, without delving into specific biological mechanisms.

Benzene as a Myelotoxin and Carcinogen

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene has been consistently linked to an increased risk of developing acute myeloid leukemia (AML), a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. The clinical presentation of AML typically includes symptoms related to bone marrow failure—such as fatigue, pallor, infection, and bleeding—due to anemia, neutropenia, and thrombocytopenia. Diagnosis is confirmed by bone marrow aspiration and biopsy showing at least 20% blasts, along with cytogenetic and molecular profiling to guide prognosis and treatment. Benzene is metabolized in the liver and bone marrow to reactive intermediates, including benzene oxide, phenol, hydroquinone, and 1,4-benzoquinone. These metabolites can form adducts with DNA and proteins, induce oxidative stress, and cause chromosomal aberrations. The carcinogenic ability of benzene has been reported, and chronic exposure to benzene can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene is acknowledged as a myelotoxin, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). Possible mechanisms of benzene initiation of hematological tumors have been identified, as a genotoxic effect, an action on oxidative stress and inflammation and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and the other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Mode of Action and Epidemiological Evidence

The mode of action (MOA) for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of acute myeloid leukaemia (AML) (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by the myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). Epidemiological studies have further quantified the association between benzene exposure and AML risk. In a meta-analysis of childhood cancers, findings indicated an elevated risk of acute lymphoblastic leukemia (ALL) in children exposed to PM2.5 (OR: 1.29, 95% CI: 1.01-1.63; 5 studies; I2 = 72.1%), and increased risks of all childhood cancers (OR: 1.12, 95% CI: 1.02-1.22; 4 studies; I2 = 0.0%) and acute myeloid leukemia (AML, OR: 1.22, 95% CI: 1.02-1.46; 4 studies; I2 = 0.0%) associated with benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). This meta-analysis provides evidence that even ambient-level benzene exposure may elevate AML risk in pediatric populations. Previous studies established a causal relationship between occupational benzene exposure and acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/38727681/). In a national cohort from Switzerland, it was found that occupational exposure to benzene is associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). This study assessed occupational exposure by applying a quantitative benzene job-exposure matrix (BEN-JEM) to census-reported occupations (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Risk Context and Causation Considerations

From a risk perspective, the adequacy of warnings regarding benzene and AML is critical. Given the established causal link, product labels and occupational safety guidelines should clearly communicate the risk of AML from benzene exposure. For affected patients, causation-related considerations include the intensity and duration of exposure, latency period, and absence of other strong risk factors. The timeline between exposure and documented harm can vary, but occupational studies suggest that AML may develop years to decades after initial benzene exposure, with higher cumulative doses associated with shorter latency. The evidence supports that benzene is a causative agent for AML, and this relationship should be reflected in medical-legal assessments and public health messaging.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does benzene cause acute myeloid leukemia?

Yes, benzene is a recognized human carcinogen and myelotoxin. Chronic exposure to benzene has been consistently linked to an increased risk of developing acute myeloid leukemia (AML). Epidemiological studies and meta-analyses have confirmed a causal relationship, with occupational exposure at levels of 10 ppm or more associated with elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What is the latency period between benzene exposure and AML?

The latency period can vary, but occupational studies suggest that AML may develop years to decades after initial benzene exposure. Higher cumulative doses are associated with shorter latency. The timeline depends on factors such as intensity, duration, and individual susceptibility.

How does benzene cause leukemia?

Benzene is metabolized in the liver and bone marrow to reactive intermediates like benzene oxide, phenol, hydroquinone, and 1,4-benzoquinone. These metabolites can form DNA adducts, induce oxidative stress, and cause chromosomal aberrations, leading to hematotoxicity and genetic toxicity. The mode of action involves multiple key events, including genotoxic effects, oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.